Co-expression of genes with estrogen receptor-α and progesterone receptor in human breast carcinoma tissue

Hormone Molecular Biology and Clinical Investigation

Volumn 12, Issue 1, 2012, Pages 377-390

  Wittliff, James L ^a   Andres, Sarah A ^b  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

breast cancer; ESR1; estrogen receptor; gene expression; PGR; progesterone receptor

Indexed keywords

COGNATE RECEPTOR PROTEIN; EOSIN; ESTROGEN RECEPTOR ALPHA; EVL PROTEIN; FUT8 PROTEIN; HEMATOXYLIN; NORADRENALIN TRANSPORTER; PROGESTERONE RECEPTOR; PTP4A2 PROTEIN; RABEP1 PROTEIN; RECEPTOR PROTEIN; SCUBE2 PROTEIN; SLC39A6 PROTEIN; TBC1D9 PROTEIN; TCEAL1 PROTEIN; TRANSCRIPTION FACTOR GATA 3; TUMOR MARKER; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

ARTICLE; BINDING ASSAY; BREAST CARCINOMA; CANCER TISSUE; ENZYME IMMUNOASSAY; FROZEN SECTION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOASSAY; TISSUE SECTION;

EID: 85009121527     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2012-0025     Document Type: Article

References (70)

1. Fleisher M., Dnistrian AM., Sturgeon CM., Wittliff JL. Practice guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis DP., Fritsche HA., Lilja H., Chan DW., Schwartz MK., editors. Tumor markers: physiology., pathobiology, technology and clinical applications. Washington D.C.: AACC Press., 2002:33-63.
2. Hammond ME., Hayes DF., Dowsett M., Allred DC., Hagerty KL., Badve S., Fitzgibbons PL., Francis G., Goldstein NS., Hayes M., Hicks DG., Lester S., Love R., Mangu PB., McShane L., Miller K., Osborne CK., Paik S., Perlmutter J., Rhodes A., Sasano H., Schwartz JN., Sweep FC., Taube S., Torlakovic EE., Valenstein P., Viale G., Visscher D., Wheeler T., Williams RB., Wittliff JL., Wolff AC. American Society_of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
3. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., Somerfield M.R., Hayes DF., Bast RC., Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
4. Wittliff JL., Pasic R., Bland KI. Steroid and peptide hormone receptors identified in breast tissue. In: Bland KI., Copeland EM., editors. The breast: comprehensive management of benign and malignant diseases. Philadelphia., PA: W. B. Saunders Co., 1998:900-36.
5. Andres SA., Wittliff JL. Relationships of ESR1 and XBP1 expression in human breast carcinoma and stromal cells isolated by laser capture microdissection compared to intact breast cancer tissue. Endocrine 2011;40:212-21.
6. Lacroix M., Leclercq G. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. Mol Cell Endocrinol 2004;219:1-7.
7. Wilson BJ., Giguere V. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer 2008;7:49.
8. KangY, Siegel PM., Shu W., DrobnjakM, Kakonen SM., Cordon-Cardo C., Guise TA., Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
9. Jansen MP., Foekens JA., van Staveren IL., Dirkzwager-Kiel MM., Ritstier K., Look MP., Meijer-van Gelder ME., Sieuwerts AM., Portengen H., Dorssers LC., Klijn JG., Berns EM. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005;23:732-40.
10. Ramaswamy S., Ross KN., Lander ES., Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
11. Sorlie T., Perou CM., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen MB., van de Rijn M., Jeffrey SS., Thorsen T., Quist H., Matese JC., Brown PO., Botstein D., Eystein LP., Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10 8 6 9-74.
12. Sotiriou C., Neo SY., McShane LM., Korn EL., Long PM., Jazaeri A., Martiat P., Fox SB., Harris AL., Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-98.
13. van't Veer LJ., Dai H., van de Vijver MJ., He YD., Hart AA., Mao M., Peterse HL., van der Kooy K., Marton MJ., Witteveen AT., Schreiber GJ., Kerkhoven RM., Roberts C., Linsley PS., Bernards R., Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
14. Wang Y., Klijn JG., Zhang Y., Sieuwerts AM., Look MP., Yang F., Talantov D., Timmermans M., Meijer-van Gelder ME., Yu J., Jatkoe T., Berns EM., Atkins D., Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
15. Ma XJ., Salunga R., Tuggle JT., Gaudet J., Enright E., McQuary P., Payette T., Pistone M., Stecker K., Zhang BM., Zhou YX., Varnholt H., Smith B., Gadd M., Chatfield E., Kessler J., Baer TM., Erlander MG., Sgroi DC. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003;100:5974-9.
16. MaXJ, Wang W., Salunga R., Tuggle JT., Stecker K., BaerTM, Erlander MG., Wittliff JL. Gene expression associated with clinical outcome in breast cancer via laser capture microdissection. Breast Cancer Res Treat 2003;82(Suppl 1):S15.
17. Wittliff JL., Ma XJ., Wang W., Salunga R., Tuggle JT., Stecker K., Wittliff TH., Erlander MG. Expression of estrogen receptor-associated genes in breast cancer cells procured by laser capture microdissection. Cincinnati., OH, USA: Jensen Symposium Abstracts., 2003.
18. Ma XJ., Wang Z., Ryan PD., Isakoff SJ., Barmettler A., Fuller A., Muir B., Mohapatra G., Salunga R., Tuggle JT., Tran Y., Tran D., Tassin A., Amon P., Wang W., Wang W., Enright E., Stecker K., Estepa-Sabal E., Smith B., Younger J., Balis U., Michaelson J., Bhan A., Habin K., Baer TM., Brugge J., Haber DA., Erlander MG., Sgroi DC. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:
19. Kerr DA., Wittliff JL. A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen. Horm Cancer 2011;2:261-71.
20. Wittliff JL., Erlander MG. Laser capture microdissection and its applications in genomics and proteomics. Methods Enzymol 2002;356:12-25.
21. Wittliff JL. Laser capture microdissection and its use in genomics and proteomics. In: Conn PM., editor. Reliable lab solutions: techniques in confocal microscopy. Boston., MA: Elsevier Press., 2010:463-77.
22. Srinivasan M., Sedmak D., Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002;161:1961-71.
23. Wittliff JL., Kunitake ST., Chu SS., Travis JC. Applications of laser capture microdissection in genomics and proteomics. J Clin Ligand Assay 2000;23:66-73.
24. Pasic R., Djulbegovic B., Wittliff JL. Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding. J Clin Lab Anal 1990;4:430-36.
25. DuPont, Medical Products Division. [3H] Progestin receptor assay kit instruction manual. Boston., MA, USA., 1988.
26. DuPont, Medical Products Division. [125I] Estrogen receptor assay kit instruction manual. Boston., MA, USA., 1989.
27. Abbott Laboratories. Abbott ER-EIA monoclonal assay. North Chicago., IL, USA., 1988.
28. Abbott Laboratories. Abbott PgR-EIA monoclonal assay. North Chicago., IL, USA., 1998.
29. Novoradovskaya N., Whitfield ML., Basehore LS., Novoradovsky A., Pesich R., Usary J., Karaca M., Wong WK., Aprelikova O., Fero M., Perou CM., Botstein D., Braman J. Universal Reference RNA as a standard for microarray experiments. BMC Genomics 2004;5:20.
30. Fisher B., Redmond C., Brown A., Wolmark N., Wittliff J., Fisher ER., Plotkin D., Bowman D., Sachs S., Wolter J., Frelick R., Desser R., LiCalzi N., Geggie P., Campbell T., Elias EG., Prager D., Koontz P., Volk H., Dimitrov N., Gardner B., Lerner H., Shibata H. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981;305:1-6.
31. Fisher B., Redmond C., Brown A., Wickerham DL., Wolmark N., Allegra J., Escher G., Lippman M., Savlov E., Wittliff J. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983;1:227-41.
32. Wittliff JL., Raffelsberger W. Mechanisms of signal transduction: sex hormones., their receptors and clinical utility. J Clin Ligand Assay 1995;18:211-35.
33. Kim C., Tang G., Baehner FL., Watson D., Constantino JP., Paik S., Shak S., Wolmark N. A comparison of estrogen receptor (ER) measurement by three methods in node negative., estrogen receptor (ER) positive breast cancer: ligand binding (LB), immunohistochemistry (IHC), and quantitative PCR. Breast Cancer Res Treat 2006;100(Suppl 1):S162-3.
34. Jeong JH., Costantino JP. Application of smoothing methods to evaluate treatment-prognostic factor interactions in breast cancer data. Cancer Invest 2006;24:288-93.
35. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001;29:2905-19.
36. Greten FR., Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 2004;206:193-99.
37. Karin M., Cao Y., Greten FR., Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
38. Clarke R., Shajahan AN., Riggins RB., Cho Y., Crawford A., Xuan J., Wang Y., Zwart A., Nehra R., Liu MC. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol 2009;114:8-20.
39. Musgrove EA., Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-43.
40. Ingenuity Sytems Pathway Analysis. 2012. Available at: http:// www.ingenuity.com/products/pathways_analysis.html.
41. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002;506-507:65-77.
42. Ragunathan N., Dairou J., Pluvinage B., Martins M., Petit E., Janel N., Dupret JM., Rodrigues-Lima F. Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition. Mol Pharmacol 2008;73:1761-8.
43. Kim SJ., Kang HS., Chang HL., Jung YC., Sim HB., Lee KS., Ro J., Lee ES. Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer. Oncol Rep 2008;19:663-8.
44. Tozlu S., Girault I., Vacher S., VendrellJ, Andrieu C., Spyratos F., Cohen P., Lidereau R., Bieche I. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens., using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006;13:1109-20.
45. Wakefield L., Robinson J., Long H., Ibbitt JC., Cooke S., Hurst HC., Sim E. Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer 2008;47:118-26.
46. Hollway GE., Maule J., Gautier P., Evans TM., Keenan DG., Lohs C., Fischer D., Wicking C., Currie PD. Scube2 mediates Hedgehog signalling in the zebrafish embryo. Dev Biol 2006;294:
47. Kawakami A., Nojima Y., Toyoda A., Takahoko M., Satoh M., Tanaka H., Wada H., Masai I., Terasaki H., Sakaki Y., Takeda H., Okamoto H. The zebrafish-secreted matrix protein you/scube2 is implicated in long-range regulation of hedgehog signaling. Curr Biol 2005;15:480-8.
48. Woods IG., Talbot WS. The you gene encodes an EGF-CUB protein essential for Hedgehog signaling in zebrafish. PLoS Biol 2005;3:e66.
49. Evangelista M., Tian H., de Sauvage FJ. The hedgehog signaling pathway in cancer. Clin Cancer Res 2006;12:5924-8.
50. Kubo M., Nakamura M., Tasaki A., Yamanaka N., Nakashima H., Nomura M., Kuroki S., Katano M. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 2004;64:6071-4.
51. Cheng CJ., Lin YC., Tsai MT., Chen CS., Hsieh MC., Chen CL., Yang RB. SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res 2009;69:3634-41.
52. Lin YC., Chen CC., Cheng CJ., Yang RB. Domain and functional analysis of a novel breast tumor suppressor protein., SCUBE2. J Biol Chem 2011;286:27039-47.
53. Gomez BP., Riggins RB., Shajahan AN., Klimach U., Wang A., Crawford AC., Zhu Y., Zwart A., Wang M., Clarke R. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J 2007;21:4013-27.
54. Ding L., Yan J., Zhu J., Zhong H., Lu Q., Wang Z., Huang C., Ye Q. Ligand-independent activation of estrogen receptor alpha_by XBP-1. Nucleic Acids Res 2003;31:5266-74.
55. Fang Y., Yan J., Ding L., Liu Y., Zhu J., Huang C., Zhao H., Lu Q., Zhang X., Yang X., Ye Q. XBP-1 increases ERalpha transcriptional activity through regulation of large-scale chromatin unfolding. Biochem Biophys Res Commun 2004;323:269-74.
56. Sengupta S., Sharma CG., Jordan VC. Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Investig 2010;2:235-43.
57. Scriven P., Coulson S., Haines R., Balasubramanian S., Cross S., Wyld L. Activation and clinical significance of the unfolded protein response in breast cancer. Br J Cancer 2009;101: 1692-98.
58. Asselin-Labat ML., Sutherland KD., Barker H., Thomas R., Shackleton M., Forrest NC., Hartley L., Robb L., Grosveld FG., van der Wees J., Lindeman GJ., Visvader JE. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007;9:201-9.
59. Fang SH., Chen Y., Weigel RJ. GATA-3 as a marker of hormone response in breast cancer. J Surg Res 2009;157:290-5.
60. Kouros-Mehr H., Bechis SK., Slorach EM., Littlepage LE., Egeblad M., Ewald AJ., Pai SY., Ho IC., Werb Z. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008;13:141-52.
61. Usary J., Llaca V., Karaca G., Presswala S., Karaca M., He X., Langerod A., Karesen R., Oh DS., Dressler LG., Lonning PE., Strausberg RL., Chanock S., Borresen-Dale AL., Perou CM. Mutation of GATA3 in human breast tumors. Oncogene 2004;23:7669-78.
62. Jacquemier J., Charafe-Jauffret E., Monville F., Esterni B., Extra JM., Houvenaeghel G., Xerri L., Bertucci F., Birnbaum D. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 2009;11:R23.
63. Parikh P., Palazzo JP., Rose LJ., Daskalakis C., Weigel RJ. GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg 2005;200:705-10.
64. Yoon NK., Maresh EL., Shen D., Elshimali Y., Apple S., Horvath S., Mah V., Bose S., Chia D., Chang HR., Goodglick L. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol 2010;41:1794-801.
65. Ciocca V., Daskalakis C., Ciocca RM., Ruiz-Orrico A., Palazzo JP. The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol 2009;40:489-95.
66. Voduc D., Cheang M., Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 2008;17:365-73.
67. Saji H., Toi M., Saji S., Koike M., Kohno K., Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett 2003;190:191-7.
68. Dahl E., En-Nia A., Wiesmann F., Krings R., Djudjaj S., Breuer E., Fuchs T., Wild PJ., Hartmann A., Dunn SE., Mertens PR. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer 2009;9:410.
69. Habibi G., LeungS, Law JH., Gelmon K., Masoudi H., Turbin D., Pollak M., Nielsen TO., Huntsman D., Dunn SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 2008;10:R86.
70. Bergmann S., Royer-Pokora B., Fietze E., Jurchott K., Hildebrandt B., Trost D., Leenders F., Claude JC., Theuring F., Bargou R., Dietel M., Royer HD. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005;65:4078-87.